Efmoroctocog Alfa

CHEMBL4297945 Phase 4 Approved Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This is a long-acting form of clotting factor VIII used to prevent and treat bleeding episodes in people with hemophilia A. It replaces the missing clotting factor that the body needs to form blood clots.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This is a long-acting form of clotting factor VIII used to prevent and treat bleeding episodes in people with hemophilia A. It replaces the missing clotting factor that the body needs to form blood clots.

Yes, Efmoroctocog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297945. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Looking for patient-friendly information?

Efmoroctocog Alfa on PillFYI

Quick Data

External Links

ChEMBL CHEMBL4297945

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.